Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens

Most phase I trials in oncology aim to find the maximum tolerated dose (MTD) based on the occurrence of dose limiting toxicities (DLT). Evaluating the schedule of administration in addition to the dose may improve drug tolerance. Moreover, for some molecules, a bivariate toxicity endpoint may be mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerard, Emma, Zohar, Sarah, Lorenzato, Christelle, Ursino, Moreno, Riviere, Marie‐Karelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292544/
https://www.ncbi.nlm.nih.gov/pubmed/34259343
http://dx.doi.org/10.1002/sim.9113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292544/
https://www.ncbi.nlm.nih.gov/pubmed/34259343
http://dx.doi.org/10.1002/sim.9113

Ejemplares similares